

To the FDA:

RE: DOCKET NO. 98N-1265

I send this letter as a consumer of healthcare services to register my concern and disapproval of the Memorandum of Understanding as published by the FDA on January 21, 1999.

In its present form, the MOU, as well as the Compounding Section 503A of the Modernization Act, severely restricts the rights of the physicians and patients to obtain healthcare products from the provider of their choice. It also infringes on the rights of compounding pharmacists to serve the public's medical needs. As a healthcare consumer, there should be no restrictions to the delivery of a compounded medication prescribed for me, regardless of where I may live or may travel. The MOU must be amended!

Signed: Christine Newman MD

State of Residence: Ca license # G25383


Comments: I am a physician who prescribes a lot of post-menopausal hormone replacement therapy; many of my patients do best on compounded estrogen and progesterone formulations. We need this option!

98N-1265

C6025

58097

5971-N86



DOCKETS MANAGEMENT BRANCH (HFA-305)  
FOOD AND DRUG ADMINISTRATION  
5630 FISHERS LN RM 1061  
ROCKVILLE MD 20857-0003

